Awareness, access, and adoption of natriuretic peptides for diagnosis of heart failure.

ABSTRACT:

Aims

This survey investigates natriuretic peptide (NP) testing in community and hospital settings, assessing awareness, accessibility, and utilization.

Methods and results

This investigator-initiated survey, conceived within the HFA of the European Society of Cardiology, comprised 14 questions. It underwent validation and pilot testing to ensure question readability and online system functionality. The survey was accessible for 87 days, from 5 April 2023 to 1 July 2023 via a web platform. There were 751 healthcare professionals across 99 countries who responded. Of them, 92.5% had access to NPs testing in hospital whereas 34.3% had no access to NTproBNP in community settings. Access to point of care NP testing was uncommon (9.6%). Public insurance fully covered NPs testing i

SUBMITTER: Bayes-Genis A 

PROVIDER: S-EPMC11770566 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature